VSAR Versartis, Inc.

19.00
+0.95  (5%)
Previous Close 18.05
Open 18.20
Price To book 5.02
Market Cap 668.95M
Shares 35,208,000
Volume 333,916
Short Ratio 4.73
Av. Daily Volume 220,900

SEC filingsSee all SEC filings

  1. 8-K - Current report 17884933
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17829111
  3. 8-K - Current report 17789275
  4. DEF 14A - Other definitive proxy statements 17781656
  5. PRE 14A - Other preliminary proxy statements 17761362

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due September 2017.
VRS-317 VELOCITY
Growth hormone deficiency, or GHD - pediatric
Phase 3 trial to be initiated 2H 2017.
VRS-317 VITAL
Growth hormone deficiency, or GHD - adult

SEC Filings

  1. 8-K - Current report 17884933
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17829111
  3. 8-K - Current report 17789275
  4. DEF 14A - Other definitive proxy statements 17781656
  5. PRE 14A - Other preliminary proxy statements 17761362
  6. CT ORDER - Confidential treatment order 17751807
  7. 8-K - Current report 17732935
  8. CT ORDER - Confidential treatment order 17728184
  9. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17719471
  10. 8-K - Current report 17709959